Viridian Therapeutics Inc

VRDN

Company Profile

  • Business description

    Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).

  • Contact

    221 Crescent Street
    Suite 103A
    WalthamMA02453
    USA

    T: +1 617 272-4600

    E: [email protected]

    https://www.viridiantherapeutics.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    143

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,624.906.60-0.08%
CAC 407,788.1038.69-0.49%
DAX 4024,038.19188.30-0.78%
Dow JONES (US)42,098.70244.95-0.58%
FTSE 1008,726.0152.04-0.59%
HKSE23,258.31123.68-0.53%
NASDAQ19,100.9498.22-0.51%
Nikkei 22537,722.401.71-0.00%
NZX 50 Index12,362.26220.07-1.75%
S&P 5005,888.5532.99-0.56%
S&P/ASX 2008,396.9010.70-0.13%
SSE Composite Index3,339.930.76-0.02%

Market Movers